Related Experiment Video
Updated: Jun 26, 2026
07:51
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
Published on: May 21, 2018
The genetics of a pharma merger
Philippe Sanseau1, Marie Chabot-Fletcher, Michael J Browne
1Molecular Discovery Research, GlaxoSmithKline, Stevenage SG1 2NY, United Kingdom.
Drug Discovery Today
|January 6, 2009
Summary
The 2000 Glaxo Wellcome-SmithKline-Beecham merger integrated R&D pipelines, offering key lessons for future pharmaceutical industry mergers and R&D portfolio strategies.
Area of Science:
- Pharmaceutical industry
- Biotechnology
- Research and Development (R&D)
Background:
- The late 20th and early 21st centuries witnessed significant consolidation in the pharmaceutical and biotech sectors through mergers and acquisitions.
- Integrating Research and Development (R&D) pipelines is a critical and complex aspect of these large-scale business combinations.
Purpose of the Study:
- To outline the combined R&D portfolio and bioinformatic strategy employed during the Glaxo Wellcome-SmithKline-Beecham merger.
- To detail the long-term lessons learned from this landmark integration of two equally sized pharmaceutical R&D organizations.
Main Methods:
- Analysis of the integrated R&D portfolio post-merger.
- Evaluation of the bioinformatic strategies implemented for data and pipeline harmonization.
- Case study approach focusing on the Glaxo Wellcome-SmithKline-Beecham merger in 2000.
Main Results:
- Successful integration of R&D pipelines was achieved, forming a unified research and development structure.
- The bioinformatic strategy facilitated the management and synergy of combined research data and drug discovery programs.
- The merger provided valuable insights into the challenges and best practices for large-scale R&D integration.
Conclusions:
- The Glaxo Wellcome-SmithKline-Beecham merger serves as a significant case study for R&D pipeline integration in the pharmaceutical industry.
- Effective bioinformatic strategies are crucial for maximizing the value and efficiency of merged R&D operations.
- Lessons learned from this merger inform future strategies for organizational integration and R&D portfolio management in the biotech and pharma sectors.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...